How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Chemicals and Materials · Forecast 2027–2033
Matrine Injection Market
- By Dosage Form: Injection Solution, Lyophilized Powder for Injection
- By Therapeutic Application: Anti-cancer Therapy, Anti-inflammatory Treatment, Antiviral Treatment, Liver Disease Management
- By End User: Hospitals, Clinics, Specialty Cancer Centers, Research Institutes
- By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Injection Solution leads By Dosage Form at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 10 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 253 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.158 →
- 11 Company Profiles 10 players: SWOT & benchmarking p.166 →
Full report · locked preview
Everything inside the Matrine Injection Market report
A complete, evidence-based study - 11 chapters and 106 sections covering market size, segmentation across 4 axes, regional analysis and 10 company profiles, forecast to 2033.
Segmentation covered
Dosage Form 2
Therapeutic Application 4
End User 4
Distribution Channel 3
Companies profiled
Tasly Pharmaceutical Group Co. Ltd.
Jiangsu Kanion Pharmaceutical Co. Ltd.
Shandong Fangming Pharmaceutical Group Co. Ltd.
Hubei Yichang Humanwell Pharmaceutical Co. Ltd.
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Guangdong Yifang Pharmaceutical Co. Ltd.
Zhejiang Tianyu Pharmaceutical Co. Ltd.
Harbin Pharmaceutical Group Co. Ltd. (Hayao)
Jiangsu Hengrui Medicine Co. Ltd.
Chengdu Kanghong Pharmaceutical Group Co. Ltd.
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
10 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Tasly Pharmaceutical Group Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Jiangsu Kanion Pharmaceutical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Shandong Fangming Pharmaceutical Group Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Hubei Yichang Humanwell Pharmaceutical Co. Ltd.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.178 →Guangdong Yifang Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Zhejiang Tianyu Pharmaceutical Co. Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Harbin Pharmaceutical Group Co. Ltd. (Hayao)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Jiangsu Hengrui Medicine Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.202 →Chengdu Kanghong Pharmaceutical Group Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.209 →
Global · 2025–2033
$2,241M by 2033 · 8.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Injection Solution76.6
- Lyophilized Powder for Injection23.4
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$395.2M → $735.9M · 8.1%
Europe$275.4M → $464.7M · 6.8%
Asia Pacific$251.5M → $437.2M · 7.2%
Latin America$155.7M → $273.3M · 7.3%
Middle East and Africa$119.7M → $249.9M · 9.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →8.112026
8.112027
8.122028
8.142029
8.152030
8.152031
8.172032
8.192033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Tasly Pharmaceutical Group Co. Ltd.19.8
- Jiangsu Kanion Pharmaceutical Co. Ltd.27.5
- Shandong Fangming Pharmaceutical Group Co. Ltd.3.9
- Hubei Yichang Humanwell Pharmaceutical Co. Ltd.8.1
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.6.2
- Guangdong Yifang Pharmaceutical Co. Ltd.6.4
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Dosage Form35.2%
Therapeutic Application21.4%
End User28.9%
Distribution Channel14.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.1
- Europe21.5
- Asia Pacific20.2
- Latin America12.6
- Middle East and Africa11.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Tasly Pharmaceutical Group Co. Ltd. | 92 | 92 | 97 | 97 | 92 | 97 | 95 |
| Jiangsu Kanion Pharmaceutical Co. Ltd. | 74 | 74 | 72 | 77 | 89 | 78 | 77 |
| Shandong Fangming Pharmaceutical Group Co. Ltd. | 71 | 85 | 85 | 68 | 80 | 85 | 79 |
| Hubei Yichang Humanwell Pharmaceutical Co. Ltd. | 66 | 66 | 78 | 61 | 61 | 74 | 68 |
| Jiangxi Qingfeng Pharmaceutical Co. Ltd. | 59 | 71 | 71 | 68 | 73 | 73 | 69 |
| Guangdong Yifang Pharmaceutical Co. Ltd. | 67 | 67 | 53 | 53 | 70 | 70 | 63 |
| Zhejiang Tianyu Pharmaceutical Co. Ltd. | 64 | 64 | 55 | 51 | 59 | 47 | 57 |
| Harbin Pharmaceutical Group Co. Ltd. (Hayao) | 53 | 41 | 46 | 50 | 51 | 46 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Tasly Pharmaceutical Group Co. Ltd.
- Jiangsu Kanion Pharmaceutical Co. Ltd.
- Shandong Fangming Pharmaceutical Group Co. Ltd.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Tasly Pharmaceutical Group Co. Ltd. | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Jiangsu Kanion Pharmaceutical Co. Ltd. | ◐ | ✓ | ◐ | ◐ | ✓ | ✓ |
| Shandong Fangming Pharmaceutical Group Co. Ltd. | ◐ | ✓ | ◐ | ✓ | ✓ | ◐ |
| Hubei Yichang Humanwell Pharmaceutical Co. Ltd. | ✓ | − | ◐ | ◐ | ◐ | ✓ |
| Jiangxi Qingfeng Pharmaceutical Co. Ltd. | − | ◐ | ✓ | ✓ | ◐ | ◐ |
| Guangdong Yifang Pharmaceutical Co. Ltd. | ◐ | ◐ | ◐ | − | ◐ | − |
| Zhejiang Tianyu Pharmaceutical Co. Ltd. | ✓ | ✓ | − | − | ◐ | − |
| Harbin Pharmaceutical Group Co. Ltd. (Hayao) | − | − | − | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Tasly Pharmaceutical Group Co. Ltd.95
2Shandong Fangming Pharmaceutical Group Co. Ltd.79
3Jiangsu Kanion Pharmaceutical Co. Ltd.77
4Jiangxi Qingfeng Pharmaceutical Co. Ltd.69
5Hubei Yichang Humanwell Pharmaceutical Co. Ltd.68
6Guangdong Yifang Pharmaceutical Co. Ltd.63
7Zhejiang Tianyu Pharmaceutical Co. Ltd.57
8Harbin Pharmaceutical Group Co. Ltd. (Hayao)48
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Tasly Pharmaceutical Group Co. Ltd.Shandong Fangming Pharmaceutical Group Co. Ltd.
Challenger3
Strong scale, closing on the leaders.
Jiangsu Kanion Pharmaceutical Co. Ltd.Hubei Yichang Humanwell Pharmaceutical Co. Ltd.Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Contender2
Focused players with pockets of strength.
Guangdong Yifang Pharmaceutical Co. Ltd.Zhejiang Tianyu Pharmaceutical Co. Ltd.
Niche1
Specialists in a single segment or region.
Harbin Pharmaceutical Group Co. Ltd. (Hayao)
Go-to-market strategy
Land Dosage Form in North America, then scale across Matrine Injection Market — a $85M beachhead inside a $1.44B market.
Beachhead (SOM)$85Mobtainable near-term
Serviceable (SAM)$585Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Injection Solution
Best fit — highest urgency & budget in Dosage Form.
Economic buyer80 fit
Lyophilized Powder for Injection
Strong fit — clear ROI and a fast path to value.
End user68 fit
Enterprise buyers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Dosage Form in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Therapeutic Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel30%
Digital / self-serve17%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Dosage Form leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Matrine Injection Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified45%
Sales qualified25%
Evaluation14%
Closed-won7%
$14.7KCAC
$63KLTV
4.3:1LTV : CAC
< 2 moCAC payback
Investment thesis
Matrine Injection Market is a resilient opportunity — $2.20B by 2033, compounding at 4.5%.
TAM · 2025$1.54Btoday
TAM · 2033$2.20Bforecast
CAGR4.5%2027–2033
Cumulative$16.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$2.20BTotal addressable market
SAM$873MServiceable available market
SOM$154MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →4.5% CAGR
Demand compounds through 2033, outpacing GDP across Dosage Form.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Dosage Form moving from early to mainstream — durable secular demand.
Consolidation upside
10+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$2.20BLarge & growingTAM by 2033 at 4.5% CAGR
$873MServiceable nowreachable with today’s model
$154MBeachhead winobtainable near-term share
10+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$1.71BBear2.9% CAGR
$2.20BBase4.5% CAGR
$2.81BBull6.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Therapeutic Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Matrine Injection Market — a $9.39B market by 2033. Plan: grow share from 7.6% to 13.8%.
Market size · 2033$9.39Btotal addressable
Market CAGR10.2%2027–2033
Target share13.8%from 7.6% today
Revenue ambition$1.30Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.6% | 13.8% | At risk |
| Revenue | $657M | $1.30B | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 32.1% | 43.0% | On track |
| Customer retention | 87.6% | 94.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Dosage Form
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Therapeutic Application capability
A defensible second engine — invest in Therapeutic Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Dosage Form share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Therapeutic Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $184M capacity & capability investment
- Greenlight bolt-on M&A in Therapeutic Application
- Authorise North America expansion plan
- Fund R&D program for Dosage Form leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossAhead
- Input-cost & supply riskBehind
- Regulatory / policy changeAt risk
- Execution & talentOn track
Sales deck · value proposition
Win the Matrine Injection Market conversation — a $3.01B market you can size, segment and defend in minutes.
Market size · 2033$3.01Btotal opportunity
Growth6.1%CAGR to 2033
Addressable buyers1,430+accounts in scope
Typical ROI6.1×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Dosage Form
Goal Grow share in Dosage Form
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.1×return on cost, year one
< 2 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
10+players profiled in this market
Coverage includes
Tasly Pharmaceutical Group Co. Ltd.Jiangsu Kanion Pharmaceutical Co. Ltd.Shandong Fangming Pharmaceutical Group Co. Ltd.Hubei Yichang Humanwell Pharmaceutical Co. Ltd.Jiangxi Qingfeng Pharmaceutical Co. Ltd.Guangdong Yifang Pharmaceutical Co. Ltd.Zhejiang Tianyu Pharmaceutical Co. Ltd.Harbin Pharmaceutical Group Co. Ltd. (Hayao)+2 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Matrine Injection Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Matrine Injection Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Chemicals and Materials · scroll →Mating Connector Market
Market size, share, segmentation and regional forecast.
$4.0B market · 2025 base year
View reportMaterial Transfer System Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportMaterial Transfer Pulley Market
Market size, share, segmentation and regional forecast.
$5.1B market · 2025 base year
View reportMaterial Test System Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMaterial Testing Services for Products and Components Market
Market size, share, segmentation and regional forecast.
$601M market · 2025 base year
View reportMaterial Testing Service Market
Market size, share, segmentation and regional forecast.
$5.7B market · 2025 base year
View reportMaterial Systems Used in 4D Printing Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportMaterials Test System Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportMaterials Testing Software Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportMaterials Testing Services Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportMaterials Testing Furnace Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportMaterials Test Grips Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.